Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Alfonso Yubero1*, Aranzazu Barquín2, Purificación Estévez3, Bella Pajares4, Luisa Sánchez5, Piedad Reche6, Jesús Alarcón7, Julia Calzas8, Lydia Gaba9, José Fuentes10, Ana Santaballa11, Carmen Salvador12, Luis Manso13, Ana Herrero14, Álvaro Taus15, Raúl Mármol16, Julia Madani17, María Merino18, Gloria Marquina19, Victoria Casado20, Manuel Constenla21, María Gutiérrez22, Alba Dosil23 and Antonio González-Martín5,24

Abstract

Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication, as well as for patients with BRCA-mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives.

Methods: In this observational, retrospective study we analysed the efficacy and safety of rucaparib within the RAP in Spain. Hospitals associated with the Spanish Ovarian Cancer Research Group (GEICO) recruited patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated with rucaparib 600 mg twice daily as maintenance or treatment (Pt-S/Pt-R) in the RAP. Baseline characteristics, efficacy, and safety data were collected.

Results: Between July 2020 and February 2021, 51 patients treated in 22 hospitals in the RAP were included in the study. Eighteen patients with a median of 3 (range, 1–6) prior treatment lines received rucaparib as maintenance; median progression-free survival (PFS) for this group was 9.1 months (95% confidence interval [CI], 4.2–11.6 months). Among 33 patients (median 5 [range, 1–9] prior treatment lines) who received rucaparib as treatment, 7 and 26 patients had Pt-S and Pt-R disease, respectively. Median PFS was 10.6 months (95% CI, 2.5 months–not reached) in the Pt-S group and 2.2 months (95% CI, 1.1–3.2 months) in the Pt-R group. Grade ≥ 3 treatment-emergent adverse events were reported in 39% of all patients, the most common being anaemia (12% and 15% in the maintenance and treatment groups, respectively). At data cut-off, 5 patients remained on treatment.

Conclusion: Efficacy results in these heavily pre-treated patients were similar to those from previous trials. The safety profile of rucaparib in real life was predictable and manageable.

Keywords: Rucaparib, Recurrent ovarian cancer, Maintenance, Treatment, PARP inhibitor

*Correspondence:
Alfonso Yubero
ayuberoe@salud.aragon.es

Full list of author information is available at the end of the article
Background
Ovarian cancer (OC) is the third most common gynaecological tumour and was the second leading cause of death from gynaecological cancer in women worldwide in 2020 [1]. Despite optimal surgery and platinum-based treatment, disease will relapse in approximately 80–85% of patients with advanced OC. Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have changed the landscape of advanced OC. Based on their efficacy and tolerability, these agents have been rapidly incorporated into the treatment algorithm. Currently, efforts in recurrent OC management are focused on maintenance treatment with anti-angiogenic drugs and PARPis [2, 3].

Rucaparib is an oral, small molecule inhibitor of PARP-1/2/3 that has shown preclinical and clinical activity in epithelial OC [4–6]. Rucaparib was approved by the European Medicines Agency (EMA) in January 2019 as maintenance for patients with recurrent platinum-sensitive (Pt-S) OC who have a complete or partial response (CR or PR) to platinum-based chemotherapy [7]. Rucaparib approval was based on the results of the ARIEL3 (NCT01968213) clinical trial, in which rucaparib significantly improved progression-free survival (PFS) over placebo across the three predefined cohorts based on genomic characteristics, regardless of the genetic background or biomarker status of the patients [5]. In Study 10 (NCT01482715), ARIEL2 (NCT01891344) and ARIEL4 (NCT02855944) [6, 8, 9], rucaparib demonstrated improved PFS in the treatment setting in patients with BRCA-mutated recurrent Pt-S or platinum-resistant (Pt-R) OC who had received two or more prior platinum chemotherapy regimens.

In March 2018, Clovis Oncology initiated the Rucaparib Access Programme (RAP) in Europe, an early access programme for the licensed indication. In addition, the RAP was designed to provide rucaparib for off-label use in patients with BRCA-mutated Pt-S or Pt-R OC and no other therapeutic options [10]. The RAP has been active in Spain since September 2018 and was closed to new patients in March 2020. Overall, 60 patients were treated in the RAP in Spain.

Here, we present results from a retrospective study conducted by the Spanish Ovarian Cancer Research Group (GEICO) in patients with recurrent OC treated with rucaparib within the RAP in Spain. The aim of the study was to understand better the management of rucaparib in a real-life setting in an unselected population, to optimise its future use.

Methods
Study design and patients
In this multicentre, retrospective, observational study, 22 GEICO-associated hospitals recruited patients treated with rucaparib within the RAP in Spain since September 2018. The study protocol was approved by the ethics committees of the participating sites and performed according to the Declaration of Helsinki and local laws and regulations. Eligible patients were adult women (≥18 years at diagnosis) with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received at least one dose of rucaparib within the RAP.

The starting dose of rucaparib was 600 mg twice daily; rucaparib could have been administered as maintenance for patients with recurrent Pt-S OC or as treatment for patients with Pt-S or Pt-R recurrent OC and a BRCA mutation. Accessible patients provided written informed consent. In accordance with Spanish laws, informed consent was not required from inaccessible patients.

Data collection and outcomes
Patient characteristics, dosing, efficacy, and safety data were collected and analysed. Patient characteristics included age, histology, mutational status of BRCA and other homologous recombination repair genes, previous relapses, previous treatment, and treatment-free interval. Rucaparib dosing data included starting dose, dose interruptions, dose reductions, treatment discontinuations, and duration of treatment. Safety data comprised all haematological and non-haematological adverse events related to rucaparib that were available in the medical records, graded according to Common Terminology Criteria for Adverse Events, version 5.0. Main efficacy parameters were investigator-assessed radiological best response by Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1, biological best response by Rustin criteria, duration of response, and investigator-assessed PFS. Patient data were extracted from source medical records available at the participating sites and entered on a web-based electronic case report form system.

Statistical methods
The study population included all available patients from the participating sites who received at least one dose of rucaparib within the RAP. The initially estimated number of participants was based on the accrual rate of the RAP until rucaparib became available in Spain. There was no formal sample size calculation. PFS was estimated using Kaplan–Meier methodology and medians were reported with associated 95% confidence intervals (CIs). All analyses were descriptive, performed in the overall population and in subgroups according to therapy setting (maintenance or treatment). In addition, PFS was analysed according to platinum sensitivity in the treatment subgroup (Pt-S or Pt-R). Descriptive subgroup analyses according to age at start of rucaparib treatment (<70 vs. ≥70 years) were prespecified. Associations between variables were tested by conventional statistical analysis.
(Pearson and/or Spearman tests). The World Programming System (WPS) platform (SAS language software) was used for all statistical analyses.

**Results**

Between July 2020 and February 2021, 51 of the 60 patients treated in the RAP were included in the study. The data cut-off date was 31st March, 2021. Eighteen patients received rucaparib as maintenance after response to platinum-based chemotherapy and 33 patients were treated with rucaparib monotherapy following progression on the previous treatment line; of these, 26 patients had Pt-R disease and 7 had Pt-S disease. Baseline characteristics of all patients are shown in Table 1.

In the maintenance group, median age was 65.5 (range 44–86) years and 94% of patients were diagnosed with epithelial OC. 72% of patients had *BRCA*-wildtype tumours and 1 patient (6%) had a *RAD51C* mutation. The median number of previous treatment lines was 3 (range 1–6) and 61% of patients had received ≥3 previous lines. Eastern Cooperative Oncology Group performance status (ECOG PS) was 1 in 56% patients, 56% of patients had achieved a PR to prior platinum-based chemotherapy and 50% of patients presented with measurable disease.

In the treatment group, median age was 63 (range 36–86) years and 91% of patients were diagnosed with epithelial OC. In 85% of patients, tumours harboured a *BRCA* mutation, and 1 patient (3%) had a *RAD51C* mutation. The median number of previous lines was 5 (range 1–9) and 55% of the patients had received ≥5 previous lines. Before initiating rucaparib, 45% and 9% of patients had ECOG PS 1 and 2, respectively, and 85% of patients presented with measurable disease.

Overall, 53% of the patients had received previous bevacizumab and 14 patients (27%) had received a prior PARPi. Of those, 1 patient received rucaparib as maintenance, 1 patient as treatment for Pt-S disease and 12 patients as treatment for Pt-R disease.

Median PFS (mPFS) in the maintenance group was 9.1 months (95% CI, 4.2–11.6) (Fig. 1). mPFS in the Pt-S and Pt-R treatment groups was 10.6 (95% CI, 2.5—not reached) and 2.2 (95% CI, 1.1–3.2) months, respectively (Fig. 2).

In the treatment group, 19 of 28 patients with measurable disease at baseline were radiologically evaluable: 4 patients with Pt-S disease and 15 patients with Pt-R disease. Nine patients were not assessable for response. In the Pt-S subgroup, 1 patient achieved a PR and 2 patients had stable disease (SD) as best response to rucaparib. Among evaluable patients with Pt-R disease, the disease control rate (CR, PR or SD) was 33% (Table 2).

Overall, treatment-emergent adverse events (TEAEs) of any grade were reported in 44 patients (86%) patients. Grade ≥3 TEAEs occurred in 39% of patients.

In the maintenance group, a TEAE of any grade occurred in 89% of patients. The most common TEAEs of any grade (reported in at least 25% patients) were nausea, alanine aminotransferase/aspartate aminotransferase increase and fatigue. Grade 3 toxicities were reported in 4 patients (22%) and there were no grade 4 TEAEs. The most common grade 3 TEAE was anaemia (11%). No grade ≥3 thrombocytopenia or neutropenia was observed (Table 3 A).

In the treatment group, 85% of patients had a TEAE, the most common being anaemia and thrombocytopenia. Grade ≥3 TEAEs were reported in 16 patients (49%), the most common being anaemia (15%). The remaining grade ≥3 TEAEs were reported in ≤2 patients (Table 3B).

Myelodysplastic syndrome (MDS) was reported in 1>70-year-old patient who received rucaparib as fourth-line treatment for Pt-R OC for more than 16 months.

All patients in the maintenance group began rucaparib at the recommended dose of 600 mg twice daily. The median treatment duration was 7.5 (range 1.1–15.5) months and 20% of patients continued treatment for >12 months. Dose interruptions and reductions were reported in 56% and 61% of patients, respectively. Only 1 patient discontinued rucaparib maintenance due to toxicity, and at the data cut-off date, 3 patients remained on treatment.

In the treatment group, 91% began rucaparib at the recommended starting dose of 600 mg twice daily. The median treatment duration was 8.6 (range 3–12) and 2.1 (range 0–16) months for patients with Pt-S and Pt-R disease, respectively. Almost all (97%) had a treatment duration <12 months. Treatment interruptions and dose reductions occurred in 63% and 44% of patients, respectively. Four patients discontinued rucaparib maintenance due to toxicity, and at the data cut-off date, 2 patients remained on treatment (Table 4).

In subgroup analyses according to age <70 vs. ≥70 years, the incidence of any-grade TEAEs was similar between subgroups (85% vs. 90%, respectively); however, grade ≥3 TEAEs were more common in the older subgroup (50%, vs. 34% in younger patients). Dose interruptions and reductions of rucaparib were also more frequent in the older subgroup (Table 5).

**Discussion**

This GEICO retrospective study evaluated the efficacy and tolerability of rucaparib in patients with recurrent OC treated in a real-world setting. The use of rucaparib in real-life, either as maintenance or treatment for recurrent OC, showed a favourable benefit-risk profile outside clinical trials in Spain.

The results from this retrospective study appear similar to previous data reported for rucaparib in pivotal clinical trials. However, the interpretation of PFS results
### Table 1: Patient populations and baseline characteristics

| Characteristic                              | Maintenance (n = 18) | Treatment (n = 33) | Total (n = 51) |
|---------------------------------------------|----------------------|--------------------|---------------|
| **Age, years**                              | 65.5 (44–86)         | 63 (36–86)         | 63 (36–86)    |
| **Diagnosis**                               |                      |                    |               |
| Epithelial ovarian cancer                   | 17 (94%)             | 30 (91%)           | 47 (92%)      |
| Fallopian tube or primary peritoneal cancer | 1 (6%)               | 3 (9%)             | 4 (8%)        |
| **Histology**                               |                      |                    |               |
| Serous                                      | 18 (100%)            | 31 (94%)           | 49 (96%)      |
| Other*†                                     | 0                    | 2 (6%)             | 2 (4%)        |
| **FIGO stage**                              |                      |                    |               |
| I/II                                        | 2 (11%)              | 2 (6%)             | 4 (8%)        |
| III                                         | 15 (83%)             | 25 (76%)           | 40 (78%)      |
| IV                                          | 1 (6%)               | 5 (15%)            | 6 (12%)       |
| Unknown                                     | 0                    | 1 (3%)             | 1 (2%)        |
| **ECOG PS**                                 |                      |                    |               |
| 0                                           | 7 (39%)              | 12 (36%)           | 19 (37%)      |
| 1                                           | 10 (56%)             | 15 (45%)           | 25 (49%)      |
| 2                                           | 0                    | 3 (9%)             | 3 (6%)        |
| Unknown                                     | 1 (6%)               | 3 (9%)             | 4 (8%)        |
| **BRCA status**                             |                      |                    |               |
| BRCA mutant                                 | 3 (17%)              | 28 (85%)           | 31 (61%)      |
| Germine†‡                                   | 2 (11%)              | 21 (64%)           | 23 (45%)      |
| Somatic†‡                                   | 1 (6%)               | 8 (24%)            | 9 (18%)       |
| BRCA wildtype                               | 13 (72%)             | 3 (9%)             | 16 (31%)      |
| Unknown                                     | 2 (11%)              | 2 (6%)             | 4 (8%)        |
| **Mutation in other HRR genes**             |                      |                    |               |
| RAD51C                                      | 1 (6%)               | 1 (3%)             | 2 (4%)        |
| **Primary cytoreductive surgery**           |                      |                    |               |
| PDS                                         | 12 (67%)             | 23 (70%)           | 35 (69%)      |
| IDS                                         | 5 (28%)              | 10 (30%)           | 15 (29%)      |
| No surgery                                  | 1 (6%)               | 0                  | 1 (2%)        |
| **Primary surgery outcome**‡                |                      |                    |               |
| R0                                          | 9 (53%)              | 22 (67%)           | 31 (62%)      |
| R1                                          | 8 (47%)              | 9 (27%)            | 17 (34%)      |
| Unknown                                     | 0                    | 2 (6%)             | 2 (4%)        |
| **Salvage surgery**                         |                      |                    |               |
| Yes                                         | 6 (35%)              | 6 (18%)            | 12 (24%)      |
| No                                          | 11 (65%)             | 27 (82%)           | 38 (76%)      |
| **Number of previous treatment lines**      |                      |                    |               |
| 1                                           | 3 (1–6)              | 5 (1–9)            | 4 (1–9)       |
| 2                                           | 2 (11%)              | 2 (6%)             | 4 (8%)        |
| 3                                           | 5 (28%)              | 3 (9%)             | 8 (16%)       |
| 4                                           | 6 (33%)              | 5 (15%)            | 11 (22%)      |
| ≥ 5                                         | 2 (11%)              | 5 (15%)            | 7 (14%)       |
| **Previous bevacizumab use**                |                      |                    |               |
| Yes                                         | 9 (50%)              | 28 (85%)           | 37 (73%)      |
| No                                          | 9 (50%)              | 5 (15%)            | 14 (27%)      |
| Unknown                                     | 0                    | 0                  | 0             |
| **Platinum status**                         |                      |                    |               |
| Platinum resistant                          | NA                   | 26 (79%)           | 26 (51%)      |
| Platinum sensitive                          | 18 (100%)            | 7 (21%)            | 25 (49%)      |
| **Measurable disease** (investigator assessed) |                  |                    |               |
| Yes                                         | 9 (50%)              | 28 (85%)           | 37 (73%)      |
| No                                          | 9 (50%)              | 5 (15%)            | 14 (27%)      |
| Unknown                                     | 0                    | 0                  | 0             |
from our study may be challenging due to the heterogeneity of the patient population and the nature of the study. For that reason, indirect comparisons using these data and any conclusions drawn from them ought to be interpreted with caution. Considering all these caveats, our results show efficacy of rucaparib in recurrent OC. In this study, the mPFS in the maintenance group was 9.1 months, while the mPFS in ARIEL3 was 10.8 months in the intention-to-treat cohort. Although slightly inferior, our results display similar PFS to ARIEL3 and the minor discordance in the median values could be explained by differences in clinical factors between the 2 populations, including \textit{BRCA} mutation status, number of previous treatment lines, and measurable disease at baseline. Compared with ARIEL3, our study included fewer patients with \textit{BRCA}-mutated tumours (17% vs. 35%) and \textit{BRCA} status was unknown in 11% of the patients. In addition, the maintenance group included a more heavily pretreated population (median number of previous lines: 3 [range, 1–6] in this study vs. 2 [range, 2–3] in ARIEL3) and more patients had measurable disease at baseline (50% vs. 38%) [5].

mPFS with rucaparib as treatment for Pt-S OC was 10.6 months, similar to the ARIEL4 clinical trial. In ARIEL4, patients were classified based on their platinum sensitivity status: partially Pt-S (platinum-free interval [PFI] ≥ 6–12 months), fully Pt-S (PFI ≥ 12 months) and Pt-R (PFI < 6 months). ARIEL4 results showed mPFS of

---

**Table 1 (continued)**

| Characteristic | Maintenance (n = 18) | Treatment (n = 33) | Total (n = 51) |
|----------------|----------------------|-------------------|---------------|
| **Response to last platinum (RECIST)** | | | |
| CR | 6 (33%) | NA | NA |
| PR | 10 (56%) | NA | NA |
| SD | 2 (11%) | NA | NA |
| **Comorbidities\(^{1}\)** | | | |
| Hypertension | 4 (22%) | 6 (18%) | 10 (20%) |
| Diabetes mellitus | 2 (11%) | 1 (3%) | 3 (6%) |
| Obesity | 2 (11%) | 0 | 2 (4%) |
| Hypothyroidism | 0 | 2 (6%) | 2 (4%) |

Data are median (range) or n (%). CR: complete response; ECOG PS: Eastern Cooperative Oncology Group performance status; FIGO: International Federation of Gynecology and Obstetrics; HRR: homologous recombination repair; IDS: interval debulking surgery; NA: not applicable; PDS: primary debulking surgery. PR: partial response. Endometrioid and clear-cell histology. 1 patient had both germline and somatic \textit{BRCA1} mutations. 1 patient from the maintenance subgroup did not undergo surgery. Most frequent comorbidities (reported in at least 2 patients)

---

**Fig. 1** Investigator-assessed PFS in the maintenance subgroup (n = 18). CI: confidence interval; mPFS: median progression-free survival; +: censored patients
12.9 and 8.0 months in patients with fully and partially Pt-S OC, respectively. In our study, the criteria to define platinum sensitivity were simplified: patients were considered to have Pt-S disease if PFI was ≥ 6 months and Pt-R disease if PFI was < 6 months. The treatment group of our study was enriched with Pt-R disease and the mPFS in this subgroup was 2.2 months, shorter than the mPFS of 6.4 months in ARIEL4 for this population. Again, some clinical factors may explain the differences. Patients treated with rucaparib in the Pt-R setting in this study represented a heavily pretreated population (median 5 previous lines [range 2–9]), and 12 of 26 patients had received a prior PARPi before rucaparib. Prior PARPi was an exclusion criterion in ARIEL4. Overall, our treatment population was less fit (9% of patients in the treatment group had ECOG PS 2 whereas patients with ECOG PS 2 were not eligible for enrolment in ARIEL4) [9]. In addition, BRCA status was wild-type or unknown in 5 patients who received rucaparib as treatment.

The overall safety profile of rucaparib in this real-life setting was acceptable and consistent with previously reported data. In our study, no new safety signals were identified, and generally, we reported a lower incidence of grade ≥ 3 TEAEs. In the maintenance group, any-grade anaemia was less frequent than in ARIEL3 (11% vs. 39%, respectively) and importantly, grade 3/4 anaemia was only half as common in our study (11% vs. 22%, respectively). Notably, no grade 3/4 neutropenia or thrombocytopenia was reported in the maintenance group (vs. 8% and 5%, respectively in ARIEL3). Regarding

**Table 2** Radiological and biological best overall response in patients with measurable disease at baseline (treatment group)

| Radiological Best Overall Response | Pt-S (n = 4) | Pt-R (n = 24) | Total (n = 28) |
|-----------------------------------|-------------|--------------|---------------|
| Investigator-assessed RECIST ORR  | 1 (25%)     | 3 (13%)      | 4 (14%)       |
| Complete response                  | 0           | 0            | 0             |
| Partial response                   | 1 (25%)     | 3 (13%)      | 4 (14%)       |
| Stable disease                     | 2 (50%)     | 2 (8%)       | 4 (14%)       |
| Progressive disease                | 1 (25%)     | 10 (42%)     | 11 (39%)      |
| Not assessable                     | 0           | 9 (38%)      | 9 (32%)       |
| **Biological best overall response**|            |              |               |
| Response                           | 1 (25%)     | 2 (8%)       | 3 (11%)       |
| Stabilisation                      | 1 (25%)     | 6 (25%)      | 7 (25%)       |
| Progression                        | 1 (25%)     | 5 (21%)      | 6 (21%)       |
| Not assessable                     | 1 (25%)     | 11 (46%)     | 12 (43%)      |

Data are n (%). ORR: objective response rate. Pt-S: platinum-sensitive disease. Pt-R: platinum-resistant disease. RECIST: Response Evaluation Criteria In Solid Tumors version 1.1

**Fig. 2** Investigator-assessed PFS in the Pt-S treatment subgroup (n = 7) and the Pt-R treatment subgroup (n = 26). CI: confidence interval; mPFS: median progression-free survival; Tx Pt-S: treatment, platinum-sensitive disease; Tx Pt-R: treatment, platinum-resistant disease; +: censored patients
non-haematological toxicities, any-grade nausea and fatigue were also less frequent in our study than in ARIEL3 (nausea: 39% vs. 76%, respectively; fatigue: 28% vs. 71%) [11]. Finally, across the entire study population, the incidence of MDS was low (1 patient with Pt-R OC), as reported previously with PARPis [5, 9, 12, 13].

The proportions of patients requiring dose reductions or treatment interruptions were similar to ARIEL3 (in the maintenance group), and to the integrated analysis of Study 10 and ARIEL2, and ARIEL4 (in the treatment group). Furthermore, the discontinuation rate was lower than in pivotal clinical trials and was caused mainly by disease progression [8, 9, 11]. As of 22nd September 2022, 4 patients remain on treatment: to date, 3 patients have been on rucaparib maintenance for 3.5–4 years and 1 patient with Pt-S OC has been on rucaparib treatment for 4 years. 1 patient with Pt-S OC discontinued rucaparib treatment due to progression after the data cut-off date.

There are some obvious limitations to our analysis, mostly inherent to the nature of non-interventional real-world studies. The patient population was heterogenous, and therapeutic decisions and patient evaluations were at the physician’s discretion and thus may not be homogeneous between sites. Differences in local testing for BRCA germline or somatic mutations could also be considered a limitation. Furthermore, data were collected retrospectively, and therefore, may be biased. Importantly, the number of patients was smaller than in the above-mentioned clinical trials. However, despite these limitations, rucaparib given as maintenance and treatment, even in an unselected and heavily pretreated population, showed a consistent efficacy and safety profile in a real-life setting.

The efficacy of PARPis as maintenance for recurrent OC has been reported in randomised clinical trials. However, there is a need for data validation in routine clinical practice treating unselected, heterogenous and, potentially, less fit patients. Few studies have evaluated real-world evidence with PARPis. The Italian MITO working group reported the results of the largest real-world study in BRCA-mutated patients treated with olaparib. As in our study, efficacy and safety observed in real-life setting for olaparib was similar to randomised clinical trials [14].

### Table 3  Most common TEAEs (reported at any grade in ≥ 2 patients) for maintenance and treatment

|                      | ALL GRADES | GRADE 3 |
|----------------------|------------|---------|
| **Maintenance (n=18)** |            |         |
| Nausea               | 7 (39%)    | 1 (6%)  |
| ALT/AST increase     | 5 (28%)    | 1 (6%)  |
| Fatigue              | 5 (28%)    | 0       |
| Diarrhoea            | 4 (22%)    | 0       |
| Creatinine increased | 4 (22%)    | 0       |
| ALP increase         | 2 (11%)    | 1 (6%)  |
| Anaemia              | 2 (11%)    | 2 (11%) |
| Neutropenia          | 2 (11%)    | 0       |
| Dysgeusia            | 2 (11%)    | 0       |
| Vomiting             | 2 (11%)    | 0       |
| Abdominal pain       | 2 (11%)    | 0       |
| Anorexia             | 2 (11%)    | 0       |
| **Treatment (n=33)**  |            |         |
| Anaemia              | 13 (39%)   | 5 (15%) |
| Thrombocytopenia     | 10 (30%)   | 2 (6%)  |
| Fatigue              | 7 (21%)    | 2 (6%)  |
| Nausea               | 5 (15%)    | 0       |
| ALT/AST increase     | 4 (12%)    | 0       |
| Neutropenia          | 3 (9%)     | 2 (6%)  |
| Vomiting             | 3 (9%)     | 2 (6%)  |
| ALP increase         | 3 (9%)     | 1 (3%)  |
| Asthenia             | 3 (9%)     | 0       |
| Abdominal pain       | 2 (6%)     | 1 (3%)  |
| Hyporexia            | 2 (6%)     | 0       |
| Constipation         | 2 (6%)     | 0       |

Data are n (%). TEAEs were graded according to Common Terminology Criteria for Adverse Events version 5.0, with the highest grade reported if patients reported the same event at more than one grade. ALP: alkaline phosphatase. ALT: alanine aminotransferase. AST: aspartate aminotransferase. TEAE: treatment-emergent adverse event.
Additional smaller series with shorter follow-up have been reported for olaparib [15, 16]. Regarding niraparib, real-world data are more sparse. A retrospective study in a real-life setting analysed niraparib safety at a starting dose of 200 mg/day in patients from the USA, but efficacy was not assessed in this study [17]. This GEICO study is, to our knowledge, the largest to report efficacy and safety data of rucaparib as maintenance and treatment of recurrent OC in a real-life setting. The results of our study not only confirm the activity of rucaparib maintenance and treatment in a real-world population of patients with recurrent OC, but also show a predictable and manageable safety profile.

Real-world data with PARPi in both the front-line and the recurrent setting are still scarce and further research is warranted. Unravelling the best biomarkers of response, establishing the optimal treatment sequence for each patient, and understanding the scenario after treatment with a prior PARPi will be crucial in the future of recurrent OC management.

### Table 4: Treatment exposure

| Parameter                                      | Maintenance (n = 18) | Treatment (n = 33) | Total (n = 51) |
|------------------------------------------------|---------------------|-------------------|---------------|
| Initial dose 600 mg twice daily                | 18 (100%)           | 30 (91%)          | 48 (94%)      |
| Treatment duration, months                     | 7.5 (1.1–15.5)      | 2.4 (0.2–16.7)    | 3.3 (0.2–16.7) |
| Treatment duration*                            |                     |                   |               |
| 0–12 months                                    | 12 (80%)            | 30 (97%)          | 42 (91%)      |
| 12–24 months                                   | 3 (20%)             | 1 (3%)            | 4 (9%)        |
| Dose interruptions†                            |                     |                   |               |
| 0                                              | 10 (56%)            | 20 (63%)          | 30 (60%)      |
| 1                                              | 8 (44%)             | 12 (38%)          | 20 (40%)      |
| 2                                              | 8 (44%)             | 13 (41%)          | 21 (42%)      |
| ≥ 3                                            | 2 (11%)             | 0                 | 2 (4%)        |
| Dose reductions†                               |                     |                   |               |
| 0                                              | 11 (61%)            | 14 (44%)          | 25 (50%)      |
| 1                                              | 7 (39%)             | 18 (56%)          | 25 (50%)      |
| 2                                              | 5 (28%)             | 11 (34%)          | 16 (32%)      |
| ≥ 3                                            | 1 (6%)              | 0                 | 1 (2%)        |
| Reason for discontinuation                     |                     |                   |               |
| Progression                                    | 13 (72%)            | 25 (76%)          | 38 (75%)      |
| Toxicity                                       | 1 (6%)              | 4 (12%)           | 5 (10%)       |
| Other†                                         | 1 (6%)              | 2 (6%)            | 3 (6%)        |
| On treatment                                   | 3 (17%)             | 2 (6%)            | 5 (10%)       |

Data are median (range) or n (%). *Percentages calculated based on patients who had discontinued treatment. †1 patient in the treatment group was excluded from the analysis as the recommended dose modification scheme was not followed. ‡Doctor’s or patient’s decision.

### Table 5: Safety and treatment exposure according to age

| Parameter                                      | < 70 years (n = 41) | ≥ 70 years (n = 10) |
|------------------------------------------------|---------------------|---------------------|
| Any grade TEAE                                 | 35 (85%)            | 9 (90%)             |
| Grade ≥ 3 TEAE                                 | 14 (34%)            | 5 (50%)             |
| Dose interruptions*                            |                     |                     |
| Yes                                            | 23 (56%)            | 7 (78%)             |
| No                                             | 18 (44%)            | 2 (22%)             |
| Dose reduction*                                |                     |                     |
| Yes                                            | 18 (44%)            | 7 (78%)             |
| No                                             | 23 (56%)            | 2 (22%)             |
| Reason for discontinuation                     |                     |                     |
| Progression                                    | 32 (78%)            | 6 (60%)             |
| Toxicity                                       | 3 (7%)              | 2 (20%)             |
| Other†                                         | 3 (7%)              | 0                   |
| On treatment                                   | 3 (7%)              | 2 (20%)             |

Data are n (%). *1 patient aged >70 years was excluded from the analysis as the recommended dose modification scheme was not followed. †Doctor’s or patient’s decision.
Conclusion

This study represents real-world evidence of patients treated with rucaparib outside clinical trials in Spain. Efficacy results of rucaparib, even in heavily pre-treated patients, are similar to those from pivotal clinical trials. The safety profile of rucaparib in a real-life setting is manageable and predictable.

List of abbreviations

ALP  alkaline phosphatase
ALT  alanine aminotransferase
AST  aspartate aminotransferase
CI  confidence interval
CR  complete response
ECOG PS  Eastern Cooperative Oncology Group performance status
EMA  European Medicines Agency
FIGO  International Federation of Gynecology and Obstetrics
GEICO  Spanish Ovarian Cancer Research Group
HRR  homologous recombination repair
IDS  interval debulking surgery
MDS  myelodysplastic syndrome
mPFS  median progression-free survival
NA  not applicable
OCR  ovarian cancer
ORR  objective response rate
PARP  poly(ADP-ribose) polymerase
PARPi  PARP inhibitor
PDS  primary debulking surgery
PFI  platinum-free interval
PFS  progression-free survival
PR  partial response
Pt-R  platinum-resistant
Pt-S  platinum-sensitive
RAP  rucaparib access programme
RECIST  Response Evaluation Criteria In Solid Tumors
SD  stable disease
TEAEs  treatment-emergent adverse events
Tx  treatment

Acknowledgements

We thank all the patients and their families and caregivers for their participation in the study and hospital staff for their contribution to the study. We thank Patricio Ledesma, Sebastià Barceló, Aina Nicolau, and Marta Padin for operational support and Cristina Adan and Ana Levin for assistance in manuscript preparation.

Authors' contribution

AY and AGM: Conceptualisation; AY and AD: Data curation; Formal analysis; AY and AGM: Funding acquisition; AY, AB, PE, BP, LS, PR, JA, JC, LG, JF, AS, CS, LM, AH, AT, RM, JM, MM, GM, VC, MC, MG: Resources; AY: Software; AY and AGM: Supervision; AY and AGM: Validation; AY, AD and AGM: Visualisation; AY, AD and AGM: Writing - original draft; All authors: Writing - review & editing.

Funding

This study was funded by Clovis Oncology. Medical writing and editorial support were funded by Clovis Oncology.

Data availability

The datasets generated and/or analysed during the current study are not publicly available due to data protection laws but are available from the corresponding author on reasonable request and with permission from GEICO.

Declarations

Ethics approval and consent to participate

The study protocol was approved by the ethics committee of HM Hospitals (Code: 20.05.1633-GHM) and performed according to the Declaration of Helsinki and local laws and regulations. Patients provided written informed consent. Informed consent was not required from inaccessible patients according to Spanish laws.

Consent to publish

Not applicable.

Conflict of interest

AY: Consulting or advisory role: Clovis Oncology, GSK, AstraZeneca, MSD, PharmaMar. Roche. Treatment, accommodation, expenses: MSD, GSK, PharmaMar. AB: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PE: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology and PharmaMar. BP: Consulting or advisory role: Clovis Oncology, Novartis, AstraZeneca. Travel, accommodation: AstraZeneca. LS: Consulting or advisory role: GSK-Tesaro, Clovis Oncology, AstraZeneca, MSD, Roche. Travel, accommodation, expenses: GSK, MSD, PharmaMar. PR: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

JA: Consulting or advisory role: GSK, Clovis, AstraZeneca, MSD. Roche. Travel, accommodation, expenses: GSK, MSD, PharmaMar. JC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

LG: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology and PharmaMar. JF: Advisory Board: Roche, AstraZeneca, Clovis Oncology and GSK.

Conflicts of interest that could have appeared to influence the work reported in this paper.

JC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

MM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

ML: Consulting or advisory role: Roche/Genentech, AstraZeneca, Novartis, Pfizer, Tesaro, Eliisa, Lilly, Clovis Oncology. Travel, accommodation, expenses: Roche, AstraZeneca, Lilly. Research Funding: Tesaro.

Conflict of interest that could have appeared to influence the work reported in this paper.

AH: Principal investigator of clinical trials: AstraZeneca, Roche. Member of advisory boards: GSK. Personal fees: Clovis Oncology, GSK, MSD and PharmaMar.

Conflict of interest that could have appeared to influence the work reported in this paper.

AT: Personal fees and non-financial support: Roche, BMS, MSD, GSK, AstraZeneca and Pfizer.

Conflict of interest that could have appeared to influence the work reported in this paper.

RM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Conflict of interest that could have appeared to influence the work reported in this paper.

JM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Conflict of interest that could have appeared to influence the work reported in this paper.

MM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Conflict of interest that could have appeared to influence the work reported in this paper.

GM: Consulting fees and honoraria for lectures, presentations, speaker bureaus: Roche, PharmaMar, GSK/Tesaro, MSD, AstraZeneca, Clovis Oncology, Medicamenta, Lilly, Pfizer.

Conflict of interest that could have appeared to influence the work reported in this paper.

VC: Consulting or advisory role: GSK, AstraZeneca, MSD, PharmaMar. Travel, accommodation, expenses: GSK, AstraZeneca, MSD, PharmaMar.

Conflict of interest that could have appeared to influence the work reported in this paper.

MC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Conflict of interest that could have appeared to influence the work reported in this paper.

MG: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Conflict of interest that could have appeared to influence the work reported in this paper.

MC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Conflict of interest that could have appeared to influence the work reported in this paper.
AstraZeneca, PharmaMar, Roche, GSK, Clovis Oncology. Research Grant/Funding: Roche, TESARO. A GSK Company. Travel/Accommodation/Expenses: AstraZeneca, PharmaMar, Roche, TESARO. A GSK Company.

Author details
1 Medical Oncology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
2 Medical Oncology, Centro Integral Oncológico Clara Campal, Madrid, Spain
3 Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
4 Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
5 Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain
6 Medical Oncology, Hospital Universitario Torrecárdenas, Almería, Spain
7 Medical Oncology, Hospital Universitario Son Espases, Mallorca, Spain
8 Medical Oncology, Hospital Universitario de Fuenlabrada, Madrid, Spain
9 Department of Medical Oncology, Translational Genomics and Targeted Therapeutics in Solid Tumors, Hospital Clínico de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (Idibaps), Barcelona, Spain
10 Medical Oncology, Hospital Universitario Virgen de Valme, Sevilla, Spain
11 Medical Oncology, Hospital Universitario i Politècnic la Fe, Valencia, Spain
12 Medical Oncology, Hospital Lluís Alcanyís de Xàtiva, Xàtiva, Spain
13 Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
14 Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain
15 Medical Oncology, Hospital del Mar, Barcelona, Spain
16 Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
17 Medical Oncology, Hospital Universitario San Jorge, Huesca, Spain
18 Medical Oncology, Hospital Universitario Infanta Sofia, Madrid, Spain
19 Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain
20 Medical Oncology, Fundación Jiménez Díaz, Madrid, Spain
21 Medical Oncology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
22 Medical Oncology, Hospital Universitario Xixón, Gijón, Spain
23 Clovis Oncology, Madrid, Spain
24 Centre for Applied Medical Research, Pamplona, Spain

Received: 10 June 2022 / Accepted: 17 October 2022

Published online: 08 November 2022

References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–40.
2. Redondo A, Guerra E, Manso L, et al. SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol. 2021;23(5):661–8.
3. Madaniga A, Bowering V, Ahnari S, Oza AM, Lheureux S. Manage wisely: poly(ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer. 2020;30(7):903–15.
4. Drew Y, Mulligan EA, Vong WT, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor APO1669 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103(4):334–46.
5. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949–61.
6. Oza AM, Tinker AV, Oza AM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267–75.
7. Rubraca (rucaparib) Summary of Product Characteristics; available at: https://www.ema.europa.eu/en/documents/product-information/rubraca-epar-product-information_en.pdf. Accessed 21 September 2022.
8. Kristeleit RS, Okaín A, Ray-Coquard I, et al. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. Int J Gynecol Cancer. 2019;29(9):1396–404.
9. Kristeleit R, Liysianskaya A, Fedenko A, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(4):465–78.
10. Clovis Oncology initiates early access program for rucaparib as treatment and as maintenance therapy in recurrent ovarian cancer in Europe. https://www.businesswire.com/news/home/20180323005344/en/Clovis-Oncology-Initiates-Early-Access-Program-Rucaparib. Accessed 2022 10th February 2022.
11. Ledermann JA, Oza AM, Lorusso D, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(5):710–22.
12. Pujaide-Lauriane E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1274–84.
13. Mirza MR, Monk BJ, Henstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.
14. Cecere SC, Giannone G, Salutari V, et al. Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: real-world data and post progression outcome. Gynecol Oncol. 2020;156(1):38–44.
15. Ni L, Cheng X, Zhou R, Xu X, Guo W, Chen X. Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China. J Ovarian Res. 2019;12(1):117.
16. Cao Y, Chen H, Huang Y, Hu H. Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau. Cancer Rep (Hoboken). 2019;2(5):e1180.
17. Gallagher JR, Heap KJ, Carroll S, Travers K, Harrow B, Westin SN. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study. Future Oncol. 2019;15(36):4197–206.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.